Special Column for Quality Research and Evaluation of Stem Cell Products (Continued)

Establishment of a real-time fluorescence quantitative PCR assay for the detection of fastidious human adenovirus*

  • DONG Ying-ying ,
  • CHEN Xiao-fei ,
  • ZHANG Tong ,
  • LIU Ming-yue ,
  • ZHANG Rui-rui ,
  • CAO Yi-dan ,
  • LI Hui-ting ,
  • FU Xin-yue ,
  • WANG Yan-hui ,
  • WANG Xin-le ,
  • CUI Meng-shan ,
  • PANG Lin ,
  • RAO Chun-ming
Expand
  • JOINN Pharmaceutical Quality Research and Testing (Beijing) Co., Ltd., Beijing 100176, China

Received date: 2024-12-13

  Online published: 2025-11-13

Abstract

Objective: To establish a high coverage, sensitive and specific TaqMan probe real-time fluorescence quantitative PCR method for the detection of Hexon gene of fastidious human adenovirus (HAdV), and to determine the fastidious HAdV in human-derived cell substrates and raw materials. Methods: In this study, primers, probes, and plasmid controls were designed and synthesized based on the conserved sequences of Hexon genes. AAV-HAdV pseudovirus was used as a positive control, the plasmid containing the gene sequence of the F subgenus of human adenovirus (HAdV-F) was used as an amplification control. The linearity, sensitivity, specificity, robustness, and reproducibility of the detection method were fully verified to ensure that it could be applied to the safety evaluation of fastidious HAdV in biologics and their raw materials. Results: A high coverage rate for virus strains was achieved by this detection method, and 100% of HAdV-F strains (94 isolates) were covered. A good linear relationship was exhibited by the plasmid controls within the range of 20-2×108 copies · μL-¹, and the R² value could reach 1.000. The detection sensitivity was able to reach 4 copies · μL-¹. Good specificity was demonstrated by this method, as specific amplifications for human adenovirus type 5 and human adenovirus type 2 could not be performed. Good robustness was also possessed by this method. When two different models of instruments were used for detection, the R2 values of the standard curves were 0.999 and 1.000 respectively, the cycle threshold (Ct) values for sensitivity were 37.22±0.62 and 36.50±0.58 respectively, and the Ct values for the positive controls were 21.67±0.03 and 20.61±0.18 respectively. No significant differences were found in the results of various detections. When two reagents of different article numbers were used for testing, the R2 values of the standard curves were both 1.000. The Ct values for sensitivity were 37.99±1.19 and 38.31±0.97 respectively, and the Ct values for the positive controls were 19.69±0.09 and 20.58±0.05 respectively. No significant differences were observed in the results of various detections. The intermediate precision was verified under the conditions of different personnel or different instruments. The detection results of the HAdV-F plasmid amplification control in four experiments were 1.29×105 copies · μL-¹, 1.54×105 copies · μL-¹, 1.73×105 copies · μL-¹, and 1.37× 105 copies · μL-¹ respectively. The relative standard deviation was calculated to be 13.2%, indicating good intermediate precision. The AAV-HAdV pseudovirus was used as a positive control for the applicability verification in human mesenchymal stem cell samples. The detection result of the positive control was determined to be 137 copies · μL-¹, and the detection result of the applicability sample was found to be 133 copies · μL-¹. The spiked sample recovery rate was calculated as 97.1%. Conclusion: The assay has good linearity, sensitivity, specificity, robustness, and reproducibility, and has high coverage of the exacting HAdV strain, which can be used for the detection of exacting HAdV in cell matrix samples for production.

Cite this article

DONG Ying-ying , CHEN Xiao-fei , ZHANG Tong , LIU Ming-yue , ZHANG Rui-rui , CAO Yi-dan , LI Hui-ting , FU Xin-yue , WANG Yan-hui , WANG Xin-le , CUI Meng-shan , PANG Lin , RAO Chun-ming . Establishment of a real-time fluorescence quantitative PCR assay for the detection of fastidious human adenovirus*[J]. Chinese Journal of Pharmaceutical Analysis, 2025 , 45(7) : 1122 -1129 . DOI: 10.16155/j.0254-1793.2024-1338

References

[1] WATANABE M,NISHIKAWAJI Y,KAWAKAMI H,et al.Adenovirus biology,recombinant adenovirus,and adenovirus usage in gene therapy[J].Viruses,2021,13(12):2502
[2] DAVISON AJ,BENKŐ M,HARRACH B.Genetic content and evolution of adenoviruses[J].J Gen Virol,2003,84(Pt 11):2895
[3] MENNECHET FJD,PARIS O,OUOBA AR,et al.A review of 65 years of human adenovirus seroprevalence[J].Expert Rev Vaccines,2019,18(6):597
[4] HENDRICKX R,STICHLING N,KOELEN J,et al.Innate immunity to adenovirus[J].Hum Gene Ther,2014,25(4):265
[5] KOSULIN K.Intestinal HAdV infection:tissue specificity,persistence,and implications for antiviral therapy[J].Viruses,2019,11(9):804
[6] 王瑞欢,陈丽丽,马学军.人腺病毒分子生物学分型检测方法的研究进展[J].实用预防医学,2021,28(3):382
WANG RH,CHEN LL,MA XJ.Research progress on molecular biological typing detection methods of human adenovirus[J].Pract Prev Med,2021,28(3):382
[7] MACNEIL KM,DODGE MJ,EVANS AM,et al.Adenoviruses in medicine:innocuous pathogen,predator,or partner[J].Trends Mol Med,2023,29(1):4
[8] GBD 2016 Diarrhoeal Disease Collaborators.Estimates of the global,regional,and national morbidity,mortality,and aetiologies of diarrhoea in 195 countries:a systematic analysis for the global burden of disease study 2016BD 2016 Diarrhoeal Disease Collaborators.Estimates of the global,regional,and national morbidity,mortality,and aetiologies of diarrhoea in 195 countries:a systematic analysis for the global burden of disease study 2016[J].Lancet Infect Dis,2018,18(11):1211
[9] JACOBSSON PA,JOHANSSON ME,WADELL G.Identification of an enteric adenovirus by immunoelectroosmophoresis(IEOP)technique[J].J Med Virol,1979,3(4):307
[10] KIDD AH,MADELEY CR.In vitro growth of some fastidious adenoviruses from stool specimens[J].J Clin Pathol,1981,34(2):213
[11] UHNOO I,SVENSSON L,WADELL G.Enteric adenoviruses[J].Baillieres Clin Gastroenterol,1990,4(3):627
[12] 中华人民共和国药典 2020年版.三部[S].2020:11
ChP 2020.Vol Ⅲ[S].2020:11
[13] Quality of biotechnological products:viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.ICH Harmonised Tripartite Guideline[J].Dev Biol Stand,1998,93:177
[14] Food and Drug Administration.Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals[S].1993
[15] Characterization and Qualification of Cell Substrates and Other Biological Materials used in the Production of Viral Vaccines for Infectious Disease Indications[S].2010
[16] SARKAR A,SAHA S,PAUL A,et al.Understanding stem cells and its pivotal role in regenerative medicine[J].Life Sci,2021,273:119270
[17] NEMBO EN,HESCHELER J,NGUEMO F.Stem cells in natural product and medicinal plant drug discovery-an overview of new screening approaches[J].Biomed Pharmacother,2020,131:110730
[18] LIN X,SUN Y,DONG X,et al.IPSC-derived CAR-NK cells for cancer immunotherapy[J].Biomed Pharmacother,2023,165:115123
[19] YAMANAKA S.Pluripotent stem cell-based cell therapy-promise and challenges[J].Cell Stem Cell,2020,27(4):523
[20] 干细胞制剂质量控制及临床前研究指导原则(试行)[S].2015
Guidelines for Quality Control of Stem Cell Preparations and Preclinical Research(Trial)[S].2015
[21] SHAHRAJABIAN MH,SUN W.The significance and importance of dPCR,qPCR,and SYBR Green PCR kit in the detection of numerous diseases[J].Curr Pharm Des,2024,30(3):169
[22] 安春艳,井良义,陈卓,等.《中国药典》与《美国药典》 《欧洲药典》 《日本药典》中聚合酶链式反应法的比较研究[J].生命科学仪器,2022,20(5):46
AN CY,JING LY,CHEN Z,et al.Comparative study of polymerase chain reaction among Chinese Pharmacopeia,United States Pharmacopeia,European Pharmacopeia,and Japanese Pharmacopeia[J].Life Sci Instrum,2022,20(5):46
[23] LU X,ERDMAN DD.Quantitative real-time PCR assays for detection and type-specific identification of the endemic species C human adenoviruses[J].J Virol Methods,2016,237:174
[24] LU X,TRUJILLO-LOPEZ E,LOTT L,et al.Quantitative real-time PCR assay panel for detection and type-specific identification of epidemic respiratory human adenoviruses[J].J Clin Microbiol,2013,51(4):1089
[25] ZHAO S,WU X,TAN Z,et al.Generation of human embryonic stem cell-derived lung organoids for modeling infection and replication differences between human adenovirus types 3 and 55 and evaluating potential antiviral drug[J].J Virol,2023,97(5):e0020923
Outlines

/